Veolity

MeVis Medical Solutions AG

Veolity LungRead is a reading solution dedicated to lung screening programs as well as incidental pulmonary nodule management. It combines lung CAD of solid, non-solid, part-solid, and calcified pulmonary nodules, automatic nodule type classification, volumetric nodule quantification, interactive temporal comparison and nodule tracking, and creates a guideline-compliant report. Veolity supports reporting according to Lung-RADS, BTS Guidelines, BC Lung Screening Protocol incl. Nodule Malignancy Risk Estimation (according to the Brock model).
Veolity’s AI automatically marks regions that are suggestive of pulmonary nodules to identify regions that demand further analysis and may have been previously overlooked by the human eye.

Information source: Vendor
Last updated: May 26, 2024

General Information

General
Product name	Veolity
Company	MeVis Medical Solutions AG
Subspeciality	Chest
Modality	CT
Disease targeted	Lung Cancer
Key-features	Nodule detection, segmentation and quantification, temporal registration and nodule comparison, report generation according to guidelines
Suggested use	Before: flagging acute findings During: perception aid (prompting all abnormalities/results/heatmaps), interactive decision support (shows abnormalities/results only on demand), report suggestion

Technical Specifications

Data characteristics
Population	Chest CTs on an asymptomatic population
Input	3D chest CT
Input format	DICOM
Output	CAD report, CAD overlay, radiology report
Output format	DICOM SR, DICOM SC, DICOM GSPS, XML, PDF, TXT
Technology
Integration	Integration in standard reading environment (PACS), Integration RIS (Radiological Information System), Integration CIS (Clinical Information System), Stand-alone third party application
Deployment	Locally on dedicated hardware, Locally virtualized (virtual machine, docker)
Trigger for analysis	Automatically, right after the image acquisition
Processing time

Regulatory

Certification
CE	Certified, Class IIa , MDR
FDA	510(k) cleared , Class II
Intended Use Statements
Intended use (according to CE)	Veolity is intended to • display a composite view of 2D cross-sections, and 3D volumes of chest CT images, • allow comparison between new and previous acquisitions as well as abnormal thoracic regions of interest, such as pulmonary nodules, • provide Computer-Aided Detection (“CAD”) findings, which assist radiologists in the detection of solid pulmonary nodules between 4-30 mm in size in CT images with or without intravenous contrast. CAD is intended to be used as an adjunct, alerting the radiologist – after his or her initial reading of the scan – to regions of interest that may have been initially overlooked. The system can be used with any combination of these features. Enabling/disabling is handled via licensing or configuration options.

Market

Market presence
On market since	03-2015
Distribution channels	Blackford, Myrian
Countries present (clinical, non-research use)	25+ (including Europe, USA, Canada, Australia, Republik of Korea, Hong Kong, New Zealand)
Paying clinical customers (institutes)	500+
Research/test users (institutes)	Veolity is used in several clinical trials world-wide
Pricing
Pricing model
Based on

Evidence

Evidence
Peer reviewed papers on performance	Assisted versus Manual Interpretation of Low-Dose CT Scans for Lung Cancer Screening: Impact on Lung-RADS Agreement (read)
Non-peer reviewed papers on performance
Other relevant papers